Results 151 to 160 of about 5,610,097 (285)

A modified homogeneity index for multi- target radiotherapy plans by subtracting high-dose subvolumes. [PDF]

PeerJ
Sang Y, Dang J, Wu J, Cai J, Su X, Wu Y.
europepmc   +1 more source

Phenotypic and genotypic characterization of single circulating tumor cells in the follow‐up of high‐grade serous ovarian cancer

Molecular Oncology, EarlyView.
Single circulating tumor cells (sCTCs) from high‐grade serous ovarian cancer patients were enriched, imaged, and genomically profiled using WGA and NGS at different time points during treatment. sCTCs revealed enrichment of alterations in Chromosomes 2, 7, and 12 as well as persistent or emerging oncogenic CNAs, supporting sCTC identity.
Carolin Salmon, Rui P. L. Neves, Nikolas H. Stoecklein, Sven‐Thorsten Liffers, Jens Siveke, Jan D. Kuhlmann, Pauline Wimberger, Paul Buderath, Rainer Kimmig, Sabine Kasimir‐Bauer   +9 more
wiley   +1 more source

Can the current radiation dose, in chest tomosynthesis, be reduced with retained image quality? A study in the context of lung cancer screening programs. [PDF]

PLoS One
Jadidi M, Svalkvist A, Båth M, Nyrén S.   +3 more
europepmc   +1 more source

Combining antibody conjugates with cytotoxic and immune‐stimulating payloads maximizes anti‐cancer activity

Molecular Oncology, EarlyView.
Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang, Dong Jun Koo, Peter M. Tessier, Greg M. Thurber   +3 more
wiley   +1 more source

Patient doses in image-guided radiotherapy: status in Europe for cone-beam CT imaging in the pelvic region. [PDF]

Radiol Oncol
Kansanoja T, Brovchuk S, Vezirovic M, Petrovic B, Amico AG, Sapignoli S, Paiusco M, Ferrari P, Sá AC, Dias AG, Teles P, Siiskonen T.   +11 more
europepmc   +1 more source

Dammarenediol II enhances etoposide‐induced apoptosis by targeting O‐GlcNAc transferase and Akt/GSK3β/mTOR signaling in liver cancer

Molecular Oncology, EarlyView.
Etoposide induces DNA damage, activating p53‐dependent apoptosis via caspase‐3/7, which cleaves PARP1. Dammarenediol II enhances this apoptotic pathway by suppressing O‐GlcNAc transferase activity, further decreasing O‐GlcNAcylation. The reduction in O‐GlcNAc levels boosts p53‐driven apoptosis and influences the Akt/GSK3β/mTOR signaling pathway ...
Jaehoon Lee, Byung‐Cheol Han, Gi‐Bang Koo, Jihye Park, Mijin Kwon, Young Bin Park, Jae‐Mun Choi, Seung‐Ho Lee, Sangho Roh   +8 more
wiley   +1 more source

Extended treatment for venous thromboembolism: Is direct oral anticoagulant dose-reduction better for all? [PDF]

Hemasphere
Lauw MN, Middeldorp S, Carrier M.
europepmc   +1 more source

TRAIL‐PEG‐Apt‐PLGA nanosystem as an aptamer‐targeted drug delivery system potential for triple‐negative breast cancer therapy using in vivo mouse model

Molecular Oncology, EarlyView.
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat, Aslihan Kucuk, Omer Erdogan, Samed Ozer, Bensu Kozan, Tugba Cuceli, Erkan Gumus, Evrim Cevik, Ozge Cevik   +8 more
wiley   +1 more source

Editorial

NORDEUROPAforum - Zeitschrift für Kulturstudien, 2013
Dose, Inken, Volquardsen, Ebbe
doaj   +1 more source

Prescription‑dose stratification improves deep learning‑based VMAT dose prediction in locally advanced NSCLC. [PDF]

Sci Rep
Chaipanya T, Nimjaroen K, Chamchod S, Intanin P, Kummanee P, Owasirikul D, Khamfongkhruea C.   +6 more
europepmc   +1 more source